Aligos Therapeutics, Inc.
ALGS- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001799448
No open-market purchases or sales by Aligos Therapeutics, Inc. insiders were filed in the last 90 days; 31 institutions reported holding it in 13F filings for Q2 2026, worth $13.2M in total; HHLR Advisors (Hillhouse) is the only superinvestor holding it.
Q4 2023 vs. Q3 2023
How the institutions holding Aligos Therapeutics, Inc. changed between Q3 2023 and Q4 2023.
All holders in Q4 2023All holders in Q3 2023
| Measure | Q3 2023 | Q4 2023 | Change |
|---|---|---|---|
| Holders | 36 | 40 | +4 |
| Shares | 25.7M | 45.4M | +19.6M (+76.2%) |
| Value | $19.2M | $30.1M | +$10.9M (+56.6%) |
New holders (9)
Institutions that held Aligos Therapeutics, Inc. at the end of Q4 2023 but not at the end of Q3 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Armistice Capital, LLC | 6,833,875 | $4.54M | 0.12% |
| Deep Track Capital, LP | 6,102,770 | $4.05M | 0.14% |
| Alyeska Investment Group, L.P. | 2,882,216 | $1.91M | 0.01% |
| Altitude Crest Partners Inc. | 2,844,681 | $1.89M | 1.26% |
| Opaleye Management Inc. | 1,297,000 | $861.2K | 0.23% |
| XTX Topco Ltd | 25,743 | $17.1K | 0.00% |
| Tower Research Capital LLC (TRC) | 18,728 | $12.4K | 0.00% |
| Two Sigma Securities, LLC | 14,739 | $9.79K | 0.00% |
| Zullo Investment Group, Inc. | 13,000 | $8.63K | 0.00% |
Sold out (5)
Institutions that held Aligos Therapeutics, Inc. at the end of Q3 2023 and filed for Q4 2023 without it.
| Institution | Shares, Q3 2023 | Value, Q3 2023 |
|---|---|---|
| Adage Capital Partners GP, L.L.C. | 1,223,278 | $913.8K |
| UBS Group AG | 5,432 | $4.06K |
| FMR LLC | 1,200 | $896 |
| Federated Hermes, Inc. | 653 | $488 |
| Newbridge Financial Services Group, Inc. | 37 | $28 |